Automated CT Measurement of Total Kidney Volume for Predicting Renal Function Decline after ¹⁷⁷Lu Prostate-specific Membrane Antigen–I&T Radioligand Therapy

Authors: Lisa Steinhelfer, Friederike Jungmann, Manuel Nickel, Georgios Kaissis, Marie-Luise Hofer, Robert Tauber, Christoph Schmaderer, Isabel Rauscher, Bernhard Haller, Marcus R. Makowski, Matthias Eiber, Rickmer F. Braren

Published: 2025-02-25

DOI: 10.1148/radiol.240427

Source: Full article

---

Abstract

A decrease in total kidney volume after lutetium 177 prostate-specific membrane antigen radioligand therapy predicted renal function decline at 12 months in patients with metastatic castration-resistant prostate cancer.